| Systematic (IUPAC) name | |
|---|---|
| (RS)-N-(2,6-dimethylphenyl)- 1-methyl-piperidine-2-carboxamide | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a603026 |
| Pregnancy cat. | C, use w/ caution, may cause fetal bradycardia |
| Legal status | ? |
| Identifiers | |
| CAS number | 96-88-8 |
| ATC code | N01BB03 |
| PubChem | CID 4062 |
| DrugBank | APRD01094 |
| ChemSpider | 3922 |
| UNII | B6E06QE59J |
| KEGG | D08181 |
| ChEBI | CHEBI:6759 |
| ChEMBL | CHEMBL1087 |
| Chemical data | |
| Formula | C15H22N2O |
| Mol. mass | 246.348 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Mepivacaine ( /mɛˈpɪvəkeɪn/) is a local anesthetic[1] of the amide type. Mepivacaine has a reasonably rapid onset (more rapid than that of procaine) and medium duration of action (shorter than that of procaine) and is marketed under various trade names including Carbocaine and Polocaine.
Mepivacaine became available in the United States in the 1960s.
Mepivacaine is used in any infiltration and regional anesthesia.
It is supplied as the hydrochloride salt of the racemate.[2]
Two primary methods of synthesis have been suggested. According to the first, mepivacaine is synthesized by reacting the ethyl ester of 1-methylpiperindine-2-carboxylic acid with 2,6-dimethylanilinomagnesium bromide, which is synthesized from 2,6-dimethylaniline and ethylmagnesium bromide.
According to the second method, reacting 2,6-dimethylaniline with the acid chloride of pyridine- carboxylic acid first gives the 2,6-xylidide of α-picolinic acid. Then the aromatic pyridine ring is reduced to piperidine by hydrogen in the presence of a platinum on carbon catalyst. The resulting 2,6-xylidide α-pipecolic acid is methylated to mepivacaine using formaldehyde with simultaneous reduction by hydrogen in the presence of platinum on carbon catalyst.
|
|||||||||||||||||||||||||